Brought to you by 
British Biotech buys Vernalis for £47.3m
27 Apr 2021
Executive Summary
Aiming to augment its product pipeline, British Biotech PLC (matrix metalloproteinase inhibitors, MMPIs) is acquiring Vernalis Group PLC (develops CNS drugs) in a stock swap transaction worth £47.3mm ($79.7mm), or over 8 times Vernalis's 2002 sales. The combined entity will create the sixth largest biotech in the UK.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Stock
- Reverse Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
British Biotech buys Vernalis for £47.3m
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice